BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20596732)

  • 1. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?
    Paesmans M; Klastersky J; Maertens J; Georgala A; Muanza F; Aoun M; Ferrant A; Rapoport B; Rolston K; Ameye L
    Support Care Cancer; 2011 Jul; 19(7):1001-8. PubMed ID: 20596732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients.
    de Souza Viana L; Serufo JC; da Costa Rocha MO; Costa RN; Duarte RC
    Support Care Cancer; 2008 Jul; 16(7):841-6. PubMed ID: 17960431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
    Ahn S; Rice TW; Yeung SJ; Cooksley T
    Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein.
    von Lilienfeld-Toal M; Dietrich MP; Glasmacher A; Lehmann L; Breig P; Hahn C; Schmidt-Wolf IG; Marklein G; Schroeder S; Stuber F
    Eur J Clin Microbiol Infect Dis; 2004 Jul; 23(7):539-44. PubMed ID: 15221617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
    Uys A; Rapoport BL; Anderson R
    Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
    Baskaran ND; Gan GG; Adeeba K
    Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk index for predicting complications and prognosis in Thai patients with neutropenia and fever.
    Chayakulkeeree M; Thamlikitkul V
    J Med Assoc Thai; 2003 Mar; 86(3):212-23. PubMed ID: 12757060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia.
    Ahn S; Lee YS; Lim KS; Lee JL
    Support Care Cancer; 2013 Aug; 21(8):2303-8. PubMed ID: 23519568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network.
    Hui EP; Leung LK; Poon TC; Mo F; Chan VT; Ma AT; Poon A; Hui EK; Mak SS; Lai M; Lei KI; Ma BB; Mok TS; Yeo W; Zee BC; Chan AT
    Support Care Cancer; 2011 Oct; 19(10):1625-35. PubMed ID: 20820815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.
    Coyne CJ; Le V; Brennan JJ; Castillo EM; Shatsky RA; Ferran K; Brodine S; Vilke GM
    Ann Emerg Med; 2017 Jun; 69(6):755-764. PubMed ID: 28041827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis.
    Zheng B; Toarta C; Cheng W; Taljaard M; Reaume N; Perry JJ
    Crit Rev Oncol Hematol; 2020 May; 149():102922. PubMed ID: 32244162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of MASCC Score for Risk Stratification in Patients of Hematological Disorders with Febrile Neutropenia.
    Taj M; Nadeem M; Maqsood S; Shah T; Farzana T; Shamsi TS
    Indian J Hematol Blood Transfus; 2017 Sep; 33(3):355-360. PubMed ID: 28824237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CISNE versus MASCC: Identifying low risk febrile neutropenic patients.
    Mohindra R; Mathew R; Yadav S; Aggarwal P
    Am J Emerg Med; 2020 Nov; 38(11):2259-2263. PubMed ID: 31864874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department.
    García de Guadiana-Romualdo L; Cerezuela-Fuentes P; Español-Morales I; Esteban-Torrella P; Jiménez-Santos E; Hernando-Holgado A; Albaladejo-Otón MD
    Biochem Med (Zagreb); 2019 Feb; 29(1):010702. PubMed ID: 30591812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Serum Procalcitonin Levels in Patients With Febrile Neutropenia Presenting to the Emergency Department.
    Yadav S; Mathew R; Sahu AK; Jamshed N; Mohindra R; Aggarwal P; Batra A; Halder D; Brunda RL
    J Emerg Med; 2021 May; 60(5):641-647. PubMed ID: 33518374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.
    Klastersky J; Paesmans M; Rubenstein EB; Boyer M; Elting L; Feld R; Gallagher J; Herrstedt J; Rapoport B; Rolston K; Talcott J
    J Clin Oncol; 2000 Aug; 18(16):3038-51. PubMed ID: 10944139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognosis prediction of febrile neutropenia by MASCC score: A retrospective study].
    Cervetti L; Vallard A; Le Moulec S; Espenel S; Falk AT; Ben Mrad M; Guy JB; Diao P; Méry B; Langrand-Escure J; Ferrand FR; Rivoirard R; Ceccaldi B; Védrine L; Magné N; Chargari C
    Bull Cancer; 2016 Jun; 103(6):561-70. PubMed ID: 27181759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas.
    Wang XJ; Goh DYT; Dorajoo SR; Chan A
    Support Care Cancer; 2017 Sep; 25(9):2815-2822. PubMed ID: 28401314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of MASCC score in the inpatient management of febrile neutropenia: a single-center retrospective study.
    Bhardwaj PV; Emmich M; Knee A; Ali F; Walia R; Roychowdhury P; Clark J; Sridhar A; Lagu T; Loh KP
    Support Care Cancer; 2021 Oct; 29(10):5905-5914. PubMed ID: 33761002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of the Multinational Association for Supportive Care in Cancer (MASCC) Risk Index Score as a Criterion for Nonadmission in Febrile Neutropenic Patients with Solid Tumors.
    Bitar RA
    Perm J; 2015; 19(3):37-47. PubMed ID: 26176568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.